• Verification code
  • Optimal Prices
    Buying products on this site guarantees the best price
  • Flexible Batches
    Flexible batch size to meet different needs of global customers
  • Prompt Delivery
    Warehouses in multiple cities to ensure timely delivery
  • Quality Assurance
    Strict process parameter control to ensure product quality
  • One-to-one Customization
    One-to-one custom synthesis for special structural needs

Dacomitinib-[d10] dihydrochloride

General Information
Catalog: BLP-002412
Molecular Formula: C24H17D10Cl3FN5O2
Molecular Weight: 552.92
Chemical Structure
Dacomitinib-[d10] dihydrochloride
Description Dacomitinib-[d10] dihydrochloride, is the labelled analogue of Dacomitinib. Dacomitinib is a medication for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR.
Synonyms Dacomitinib D10 dihydrochloride
IUPAC Name (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(2,2,3,3,4,4,5,5,6,6-decadeuteriopiperidin-1-yl)but-2-enamide;dihydrochloride
Related CAS 1110813-31-4 (unlabelled free base)
Canonical SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4.Cl.Cl
InChI InChI=1S/C24H25ClFN5O2.2ClH/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31;;/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29);2*1H/b6-5+;;/i2D2,3D2,4D2,9D2,10D2;;
InChI Key LXKDPSJRGPJVSA-CGPQFTACSA-N
Purity > 98%

Interested in our Service & Products?
Need detailed information?

USA
  • International: 1-631-504-6093
  • US & Canada (Toll free): 1-844-BOC(262)-0123
  • 45-16 Ramsey Road, Shirley, NY 11967, USA
  • Email: info@bocsci.com
  • Fax: 1-631-614-7828
UK
  • 44-20-3286-1088
  • 85 Great Portland Street, London, W1W 7LT
  • Email: info@bocsci.com
Copyright © 2025 BOC Sciences. All Rights Reserved.
0
Inquiry Basket

No data available, please add!

Delete selectedGo to checkout

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x